Actualités

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches. Speaking at a Gol

Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built dividend portfolio pays you on a schedule independent of whether you showed up to work or whether your employer hit its quarter. Real ... Earn $5,000+ Yearly With These 4 Dividend Stocks

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.

With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.

(Bloomberg) -- GSK Plc agreed to buy Nuvalent Inc. for $10.6 billion, securing a US biotech firm developing treatments for lung cancer as part of the British pharmaceutical company’s effort to rebuild its oncology franchise.Most Read from BloombergHouse Republican Says Hegseth’s D-Day Remarks ‘Inappropriate’LA Mayor Race Flips as Socialist Beats Reality TV Star PrattTrump’s $100,000 H-1B Visa Application Fee Rejected by JudgeTrump Says He, Not Congress, Is in Charge of Kennedy Center in Reversal

New data showed ecnoglutide outperformed semaglutide in a China study of 163 patients.

More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.

Pacer US Cash Cows 100 ETF (NYSEARCA:COWZ) owns the 100 Russell 1000 names that generate the most free cash flow relative to market value. That pitch has worked. COWZ trades around $64 and is up 17% over the past year. But the engine powering the fund depends on one variable holding up across cyclical sectors, ... Watch Out, Rising Capex Could Turn Today’s Cash Cows Into Dogs

The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.

The drugmaker's recent outperformance is a sideshow to its more valuable, long-term trait for investors.

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.

Pfizer Inc. recently presented detailed Phase 2b results for berobenatide (PF’3944), an investigational once-weekly and once-monthly GLP-1 receptor agonist, showing proof of concept for meaningful weight loss with low gastrointestinal side effects across obesity and type 2 diabetes populations. The company is now planning more than 10 Phase 3 trials for berobenatide in 2026, signaling an attempt to build a broad obesity and comorbidity franchise that could reshape Pfizer’s mix of future...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

Investing.com -- Pfizer Inc (NYSE:PFE) has unveiled detailed strategy plans and clinical data for its experimental weight-loss injection, aiming to secure a foothold in a competitive market currently dominated by rivals. The New York-based pharmaceutical giant is working to catch up to industry leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), which have captured significant market share through their first-mover advantages. Following earlier clinical setbacks, Pfizer rev

Why Pfizer (PFE) is on investors’ radar today Pfizer (PFE) is back in focus after recent share price moves, with the stock closing at $26.04. For investors, the key question is how this current level lines up with its fundamentals. See our latest analysis for Pfizer. The 1-day share price return of 1.36% comes after a mixed few months, with the 90-day share price return down 3.73% and the 1-year total shareholder return at 19.31%. This points to improving momentum from a still-recovering...

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor

According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai-3 model.

Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.

Pfizer (NYSE:PFE) has entered a new licensing agreement with Chai Discovery to use artificial intelligence models for biologics drug discovery. The partnership focuses on applying advanced AI to identify and design potential therapeutic candidates across Pfizer's research programs. This development comes as large drug makers explore ways to use AI to streamline R&D and widen their pipelines. Pfizer shares most recently closed at $25.34, with the stock up 15.9% over the past year and down...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AbbVie's FDA approval of Decnupaz for BPDCN marks its first blood cancer ADC and expands a strategy built on deals and internal development.

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.

Durability, not yield, is the deciding factor.

Adaptive Biotechnologies (NASDAQ:ADPT) Chief Executive Officer and Co-Founder Chad Robins said the company is focused on expanding its minimal residual disease testing business while pursuing targeted partnerships for its Immune Medicine platform, during a presentation at William Blair’s Growth Stoc